-
Risk Reduction, Clinical Trials Are Focus of Atlanta Community EventCancer researchers, patient advocates and community members gathered for a public forum presented by the American Association for Cancer Research.
by Kevin McLaughlin
-
Making Clinical Trials More InclusiveBroadening clinical trial eligibility criteria to include cancer patients who also have other health conditions could increase trial enrollment.
by Ashley P. Taylor
-
What Do Clinical Trial Endpoints Really Measure?A study investigates whether a commonly used clinical trial endpoint, progression-free survival, can be used to predict quality of life.
by Jon Kelvey
-
2018: This Year in Cancer NewsThe Cancer Today editorial staff selects some of the most interesting and impactful reporting, research and perspectives of 2018.
by Cancer Today Staff
-
2018 SABCS: Choosing the Right TreatmentStudies presented at the 2018 San Antonio Breast Cancer Symposium investigate when patients with early-stage breast cancer or precancerous breast conditions benefit from receiving less intense treatment.
by Kate Yandell
-
The Roots of Rural Health DisparitiesNew research shows that rural cancer patients have the same health outcomes as urban cancer patients so long as they are involved in a clinical trial.
by Cheryl Platzman Weinstock
-
Will Right to Try Increase Access to Experimental Treatments?The recently passed Right to Try Act is meant to provide patients with greater access to experimental therapies. Patient advocates are divided on whether the law will benefit patients.
by Marci A. Landsmann
-
Omitting ObesityMany cancer clinical trials do not track what proportion of enrolled patients are obese, a study finds. These patients may be underrepresented in research.
by Cici Zhang
-
Non–Small Cell Lung Cancer Takes Center StageA trio of clinical trials at the AACR Annual Meeting spotlight new avenues for non-small cell lung cancer treatment.
by Brad Jones
-
Pembrolizumab Shows Further Promise for MelanomaIn a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected.
by Brad Jones
Scientists present data on the risks of immune checkpoint inhibitors so more patients can tap into the treatment.
by Marci A. Landsmann
Tissue and Liquid Biopsy for Targeted TherapyTailored treatments led to better outcomes than standard of care when biomarker results from liquid biopsy and tumor tissue aligned.
by Eric Fitzsimmons
Cancer Vaccines Show Promise in Early TrialsWhile mRNA vaccines offer a personalized approach to triggering an immune response, peptide vaccines could be a one-size-fits-all treatment. Researchers are exploring both options.
by Thomas Celona
Declining Breast Cancer Mortality in Younger WomenU.S. breast cancer deaths declined for women ages 20 to 49, which researchers credit to wider screening and better treatment.
by Kevin McLaughlin
-
Inaugural AACR IO Conference Kicks Off With Celebration of Immune CheckpointsImmune checkpoint icons James Allison and Arlene Sharpe shared their journeys and a look ahead on the opening night of the inaugural AACR IO conference.
-
A New Resource Provides a Sanctuary for Black TNBC PatientsThe Black TNBC Sanctuary was created to help Black women with triple-negative breast cancer get answers about their diagnosis and care.
Dr. Humberto M. Guiot: Targeting Pancreatic Cancer in a Community-Based Clinical Trial
